[Comparison of single infusion of anti-BCMA versus combined infusion of anti-CD19 chimeric antigen receptor T cells for immune reconstruction in relapsed/refractory multiple myeloma] [0.03%]
单次输注抗-BCMA与联合输注抗-CD19嵌合抗原受体T细胞在复发/难治性多发性骨髓瘤免疫重建中的比较研究
J Ge,T T Zhao,C Y Wan et al.
J Ge et al.
Objective: We observed and compared the differences in immune reconstruction between single-infusion anti-B-cell maturation antigen (BCMA) , chimeric antigen receptor T cells (CAR-T) , and combined infusion of anti-CD19 CAR-T cells in the t...
[Chinese expert consensus on prevention and treatment of immunotherapeutic and molecular targeted agents-related infections in patients with hematological malignancies (2021 version)] [0.03%]
《中国专家共识-血液系统恶性肿瘤患者免疫和分子靶向药物治疗相关感染防治(2021年版)》
Infectiology Group, Chinese Society of Hematology, Chinese Medical Association;Lymphocytic Disease Group et al.
Infectiology Group et al.
[Chinese guidelines for diagnosis and treatment of adult acute lymphoblastic leukemia (2021)] [0.03%]
中国成人急性淋巴细胞白血病诊断与治疗指南(2021版)
Hematology Oncology Committee, Chinese Anti-Cancer Association;Leukemia & Lymphoma Group, Chinese Society of Hematology et al.
Hematology Oncology Committee et al.
G H Li,C Liu,W W Qin et al.
G H Li et al.
[Treatment of extramedullary recurrent multiple myeloma with daretozumab in combination with the DECP regimen: a case report] [0.03%]
[达雷妥祖单抗联合DECP方案治疗髓外复发多发性骨髓瘤一例]
Z L Wei,L Q Huang,J W Yan et al.
Z L Wei et al.
[Treatment of PCM1-JAK2-positive myeloproliferative neoplasm with eosinophilia using ruxolitinib: a case report] [0.03%]
使用鲁索利替尼治疗PCM1-JAK2阳性嗜血性髓系增生性肿瘤一例报告
Y Song,Y R Zhang,Y Han et al.
Y Song et al.
[A family with hereditary FⅪ deficiency caused by compound heterozygous mutation] [0.03%]
[由复等位基因突变导致的遗传性FⅪ缺乏家系]
X Y Zheng,Y H Jin,Y Y Xu et al.
X Y Zheng et al.